Definium Therapeutics is trading at $39.95 (+4.88%), possibly as investors position ahead of Panorama, a Phase 3 generalized-anxiety study whose topline results were expected in September 2026.
- No fresh company-specific announcement dated September 8, 2026 was identified.
- Earlier positive Voyage results showed statistically significant efficacy and may continue supporting sentiment, but the August 12 announcement does not directly explain today’s move.
- Broader markets are mixed-to-lower, providing limited support for a global-market explanation.